TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe
TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), has announced a strategic partnership with Avantor, Inc. (NYSE: AVTR) to expand its nucleic acid products distribution across Europe, Middle East, and Africa (EMEA). The collaboration aims to streamline ordering processes and reduce lead times for European customers.
The partnership will increase accessibility to TriLink's product portfolio, including CleanCap® cap analogs, catalog mRNAs, modified and unmodified nucleotides, and CleanScribe® RNA Polymerase. These products will be available for research use only (RUO) or at GMP-grade through VWR's eCommerce platform, MarketSource.
TriLink, with over 25 years of experience in nucleic acid development, offers CDMO services and specializes in mRNA capping analogs, including CleanCap® M6, mRNA raw materials, and advanced scale-up capabilities.
TriLink BioTechnologies, una società di Maravai LifeSciences (NASDAQ: MRVI), ha annunciato una partnership strategica con Avantor, Inc. (NYSE: AVTR) per espandere la distribuzione dei suoi prodotti a base di acidi nucleici in Europa, Medio Oriente e Africa (EMEA). La collaborazione mira a semplificare i processi di ordinazione e ridurre i tempi di consegna per i clienti europei.
La partnership aumenterà l'accessibilità al portafoglio prodotti di TriLink, che include analoghi di cap CleanCap®, mRNA di catalogo, nucleotidi modificati e non modificati, e CleanScribe® RNA Polymerase. Questi prodotti saranno disponibili solo per uso di ricerca (RUO) o di qualità GMP tramite la piattaforma eCommerce di VWR, MarketSource.
TriLink, con oltre 25 anni di esperienza nello sviluppo di acidi nucleici, offre servizi CDMO e si specializza in analoghi di capping per mRNA, inclusi CleanCap® M6, materie prime per mRNA e capacità avanzate di scalabilità.
TriLink BioTechnologies, una compañía de Maravai LifeSciences (NASDAQ: MRVI), ha anunciado una alianza estratégica con Avantor, Inc. (NYSE: AVTR) para expandir la distribución de sus productos de ácidos nucleicos en Europa, Medio Oriente y África (EMEA). La colaboración tiene como objetivo simplificar los procesos de pedidos y reducir los plazos de entrega para los clientes europeos.
La alianza aumentará el acceso al portafolio de productos de TriLink, que incluye análogos de cap CleanCap®, mRNAs de catálogo, nucleótidos modificados y no modificados, y CleanScribe® RNA Polymerase. Estos productos estarán disponibles solo para uso de investigación (RUO) o en calidad GMP a través de la plataforma de comercio electrónico de VWR, MarketSource.
TriLink, con más de 25 años de experiencia en el desarrollo de ácidos nucleicos, ofrece servicios CDMO y se especializa en análogos de capping de mRNA, incluidos CleanCap® M6, materia prima de mRNA y capacidades avanzadas de escalado.
TriLink BioTechnologies는 Maravai LifeSciences 회사(NASDAQ: MRVI)로, Avantor, Inc.(NYSE: AVTR)와의 전략적 파트너십을 발표하여 유럽, 중동 및 아프리카(EMEA) 전역에서 핵산 제품 배급을 확대하고 있습니다. 이 협력의 목표는 유럽 고객을 위한 주문 프로세스를 간소화하고 리드 타임을 단축하는 것입니다.
이 파트너십을 통해 CleanCap® 캡 아날로그, 카탈로그 mRNA, 변형 및 비변형 뉴클레오타이드, CleanScribe® RNA 중합효소를 포함한 TriLink의 제품 포트폴리오에 대한 접근성이 증가할 것입니다. 이러한 제품은 연구용(RUO)으로만 또는 GMP 등급으로 VWR의 전자 상거래 플랫폼인 MarketSource를 통해 제공됩니다.
TriLink는 25년 이상의 핵산 개발 경험을 보유하고 있으며, mRNA 캡 아날로그인 CleanCap® M6, mRNA 원자재 및 고급 스케일업 능력을 포함한 CDMO 서비스를 전문으로 합니다.
TriLink BioTechnologies, une entreprise de Maravai LifeSciences (NASDAQ: MRVI), a annoncé un partenariat stratégique avec Avantor, Inc. (NYSE: AVTR) pour étendre la distribution de ses produits d'acides nucléiques en Europe, au Moyen-Orient et en Afrique (EMEA). La collaboration vise à simplifier les processus de commande et à réduire les délais de livraison pour les clients européens.
Ce partenariat augmentera l'accessibilité au portefeuille de produits de TriLink, y compris les analogues de cap CleanCap®, les ARN messagers de catalogue, les nucléotides modifiés et non modifiés, ainsi que la polymérase d'ARN CleanScribe®. Ces produits seront disponibles uniquement à des fins de recherche (RUO) ou de qualité GMP via la plateforme de commerce électronique de VWR, MarketSource.
TriLink, fort de plus de 25 ans d'expérience dans le développement d'acides nucléiques, propose des services CDMO et se spécialise dans les analogues de coiffe pour ARN messagers, y compris CleanCap® M6, les matières premières en ARN messager et des capacités avancées d'évolutivité.
TriLink BioTechnologies, ein Unternehmen von Maravai LifeSciences (NASDAQ: MRVI), hat eine strategische Partnerschaft mit Avantor, Inc. (NYSE: AVTR) angekündigt, um die Verteilung seiner Nukleinsäureprodukte in Europa, dem Nahen Osten und Afrika (EMEA) auszubauen. Das Ziel der Zusammenarbeit ist es, die Bestellprozesse zu optimieren und die Lieferzeiten für europäische Kunden zu verkürzen.
Die Partnerschaft wird den Zugang zum Produktportfolio von TriLink erhöhen, das CleanCap® Kappenanaloga, Katalog-mRNAs, modifizierte und nicht modifizierte Nukleotide sowie CleanScribe® RNA-Polymerase umfasst. Diese Produkte werden nur für Forschungszwecke (RUO) oder in GMP-Qualität über die eCommerce-Plattform von VWR, MarketSource, verfügbar sein.
TriLink bietet seit über 25 Jahren Erfahrung in der Entwicklung von Nukleinsäuren CDMO-Dienste an und ist auf mRNA-Capping-Analoga spezialisiert, einschließlich CleanCap® M6, RNA-Rohmaterialien und überlegene Skalierungskapazitäten.
- Expanded market reach into EMEA region through Avantor's distribution network
- Improved operational efficiency with streamlined ordering process and reduced lead times
- Enhanced product accessibility through VWR's eCommerce platform
- None.
Insights
The strategic partnership between TriLink BioTechnologies and Avantor represents a calculated move to capitalize on the rapidly expanding nucleic acid therapeutics market in EMEA, which is experiencing substantial growth driven by mRNA vaccine development and gene therapy advancements. The collaboration addresses several critical market dynamics:
The integration with VWR's MarketSource platform significantly enhances TriLink's market penetration capability, providing a robust digital infrastructure that can accelerate order processing and fulfillment. This digital transformation is particularly important as the industry moves toward more streamlined procurement processes.
Key strategic advantages include:
- Reduced lead times and improved logistics efficiency, which are critical factors in the time-sensitive biotech research and development process
- Access to Avantor's established customer base and distribution network, potentially accelerating market share growth
- Enhanced availability of TriLink's proprietary CleanCap® technology, which is essential for mRNA therapeutic development
From a market perspective, this partnership positions Maravai LifeSciences (MRVI) to better compete in the European biotech sector, where demand for nucleic acid products is surging due to increased investment in mRNA therapeutics and personalized medicine. The timing aligns with the industry's shift toward localized supply chains and faster access to critical research materials.
While the immediate revenue impact may be modest, the long-term strategic value lies in establishing a stronger European presence and creating a more efficient distribution system that can scale with market demand. This move strengthens MRVI's competitive position against other players in the nucleic acid space and provides a foundation for future growth in the EMEA region.
Partnership streamlines ordering process & reduces lead times to support TriLink’s European customer projects from start to finish
With over 25 years of experience in nucleic acid product development and manufacturing, TriLink is an established industry leader focused on advancing mRNA-based therapeutic innovations. Through the agreement, TriLink’s products will now be more widely available in EMEA, including its CleanCap® cap analogs (co-transcriptional mRNA caps), catalog mRNAs, over 150 modified and unmodified nucleotides, and high-performance IVT enzymes like CleanScribe® RNA Polymerase – all of which can be adapted for research use only (RUO) or manufactured at GMP-grade. Additionally, TriLink products will be available through VWR’s eCommerce platform, MarketSource, in the coming months.
“This partnership marks an important step in expanding access to our cutting-edge nucleic acid technologies across Europe,” said Becky Buzzeo, Chief Commercial Officer at TriLink. “By collaborating with a trusted partner like Avantor and leveraging their unmatched distribution network, we can better serve the region’s growing demand for innovative solutions and support the advancement of life-changing therapeutic research.”
TriLink is dedicated to advancing nucleic acid therapeutics, vaccines, and diagnostics by providing its customers with high-quality technology and chemistry and Contract Development and Manufacturing Organization (CDMO) services. Its growing portfolio of mRNA capping analogs includes the award-winning CleanCap® M6, mRNA raw materials (nucleotides and other IVT enzymes including wild-type T7 RNA polymerase), advanced scale-up capabilities, and unrivaled expertise in mRNA, oligonucleotide, and enzyme production.
To learn more about TriLink’s products and services, visit trilinkbiotech.com
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans. For more information, visit trilinkbiotech.com
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com
Forward-looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203316656/en/
Investor Contact:
Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Media Contact:
Liz Robinson of CG Life
TriLink BioTechnologies
+1 312-997-2436
lrobinson@cglife.com
Source: TriLink BioTechnologies
FAQ
What is the impact of TriLink's partnership with Avantor on MRVI's European market presence?
Which TriLink products will be available through Avantor's distribution network?
How will MRVI's products be distributed through Avantor's network?
What are the key benefits of the MRVI-Avantor partnership for European customers?
